CL2014000175A1 - Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. - Google Patents
Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.Info
- Publication number
- CL2014000175A1 CL2014000175A1 CL2014000175A CL2014000175A CL2014000175A1 CL 2014000175 A1 CL2014000175 A1 CL 2014000175A1 CL 2014000175 A CL2014000175 A CL 2014000175A CL 2014000175 A CL2014000175 A CL 2014000175A CL 2014000175 A1 CL2014000175 A1 CL 2014000175A1
- Authority
- CL
- Chile
- Prior art keywords
- oxo
- compound
- cancer
- benzazepin
- butanamide
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US201161560486P | 2011-11-16 | 2011-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000175A1 true CL2014000175A1 (es) | 2014-08-22 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000175A CL2014000175A1 (es) | 2011-07-27 | 2014-01-23 | Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. |
Country Status (36)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350216B2 (en) | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| EP3024456A4 (en) | 2013-07-26 | 2017-04-12 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) * | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| EP3414239A2 (en) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc. | Inhibitors of receptor-interacting protein kinase 1 |
| MY199967A (en) | 2016-03-15 | 2023-11-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| US11564929B2 (en) * | 2016-04-12 | 2023-01-31 | Eli Lilly And Company | Combination therapy with Notch and PI3K/mTOR inhibitors for use in treating cancer |
| KR102418765B1 (ko) * | 2016-04-12 | 2022-07-08 | 일라이 릴리 앤드 캄파니 | 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법 |
| KR102463617B1 (ko) | 2016-05-20 | 2022-11-03 | 일라이 릴리 앤드 캄파니 | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 |
| CN116473978A (zh) * | 2016-08-31 | 2023-07-25 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| SI3552017T1 (sl) | 2016-12-09 | 2022-09-30 | Denali Therapeutics Inc. | Spojine uporabne kot zaviralci RIPK1 |
| KR20190116420A (ko) | 2017-02-17 | 2019-10-14 | 프레드 헛친슨 켄서 리서치 센터 | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 |
| TW201932482A (zh) | 2017-11-01 | 2019-08-16 | 美商奇諾治療有限公司 | 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸 |
| CN111886012A (zh) | 2017-11-06 | 2020-11-03 | 朱诺治疗学股份有限公司 | 细胞疗法与γ分泌酶抑制剂的组合 |
| BR112020022654A2 (pt) * | 2018-05-06 | 2021-03-09 | Ayala Pharmaceuticals Inc. | Composições de combinação que compreendem compostos de bisfluoroalquil-1,4-benzodiazepinona e métodos de uso das mesmas |
| MX2021003773A (es) | 2018-10-02 | 2021-07-16 | Frequency Therapeutics Inc | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. |
| CN114340611A (zh) | 2019-04-08 | 2022-04-12 | 频率医疗公司 | 用于治疗听力损失的chir99021和丙戊酸的组合 |
| EP4463229A1 (en) | 2022-01-12 | 2024-11-20 | Denali Therapeutics Inc. | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9711537B (en) * | 1996-12-23 | 1998-06-25 | Athena Neurosciences Inc Eli L | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds. |
| JP2002518481A (ja) | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物 |
| CA2325389A1 (en) * | 1998-06-22 | 1999-12-29 | James E. Audia | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| JP4662914B2 (ja) | 2003-02-04 | 2011-03-30 | エフ．ホフマン−ラ ロシュ アーゲー | ガンマ−セクレターゼ阻害剤としてのマロンアミド誘導体 |
| NZ545538A (en) | 2003-09-09 | 2008-12-24 | Hoffmann La Roche | Malonamide derivatives blocking the activity of gama-secretase |
| US7166587B2 (en) | 2003-10-06 | 2007-01-23 | Hoffmann-La Roche Inc. | Carbamic acid alkyl ester derivatives |
| CN101410378B (zh) | 2006-03-27 | 2012-12-05 | 霍夫曼-拉罗奇有限公司 | 作为γ分泌酶抑制剂的丙二酰胺衍生物 |
| CN101622232A (zh) * | 2007-02-02 | 2010-01-06 | 弗·哈夫曼-拉罗切有限公司 | 6-氧代-6,7-二氢-5h-二苯并[b,d]氮杂䓬-7-基衍生物 |
| RU2010133489A (ru) | 2008-01-11 | 2012-02-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение ингибиторов гамма-секретазы для лечения рака |
| US8637493B2 (en) * | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en not_active Ceased
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en active Active
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
-
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014000175A1 (es) | Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| CL2009000448A1 (es) | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. | |
| CL2014000511A1 (es) | Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer. | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| MY177344A (en) | Compounds and their methods of use | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| CO6700837A2 (es) | Proceso de elaboración para derivados de prrimidina | |
| CL2015002628A1 (es) | Compuestos de heteroarilo y sus usos. | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| PH12018500071A1 (en) | Plinabulin compositions | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
| PE20130212A1 (es) | Formas polimorficas de st-246 y metodos de preparacion | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| CL2014001323A1 (es) | Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
| MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. | |
| PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug |